Ovarian Cancer Clinical Trial
Official title:
Integration of Palliative Care in Use of Intra-Peritoneal Chemotherapy for Ovarian Cancer
RATIONALE: Palliative care may help improve the quality of life of patients with ovarian
cancer who are undergoing intraperitoneal chemotherapy.
PURPOSE: This clinical trial is studying palliative care in patients with ovarian cancer who
are undergoing intraperitoneal chemotherapy.
OBJECTIVES:
- Describe symptoms/concerns before, during, and after intraperitoneal (IP) chemotherapy
and the impact of these symptoms/concerns on the quality of life (QOL) of patients with
ovarian cancer undergoing IP chemotherapy. (Part I)
- Analyze care received and resource utilization of these patients, including length of
hospitalization, ICU admission rates, clinic visits, phone calls, urgent care visits,
and other heath system encounters. (Part I)
- Develop palliative care assessment measures and interventions that apply to IP
chemotherapy. (Part II)
- Implement a palliative care intervention in a pilot of 6 patients. (Part II)
- Describe the impact of implementing palliative care interventions on resource
utilization, improved QOL and symptoms, and number of chemotherapy courses completed.
(Part II)
OUTLINE: This is a two-part study.
- Part I (retrospective portion): Patients who have undergone intraperitoneal (IP)
chemotherapy within the past 6-12 months undergo a retrospective interview and chart
audit to identify their needs and experiences.
- Part I (prospective portion): Patients are followed monthly for up to 6 months during
IP chemotherapy to provide information about usual care and to identify needs and
palliative care concerns. Patients also complete a quality-of-life (QOL) questionnaire
(COH QOL Ovarian tool) and undergo a prospective interview.
- Part II (intervention): Patients undergo comprehensive palliative care assessment, a
patient teaching session prior to the initiation of IP chemotherapy, and a palliative
care intervention during IP chemotherapy. Patients also complete a QOL questionnaire
and undergo an interview. Patients are followed monthly for up to 6 months during IP
chemotherapy.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |